Richmond-based Company Poised to Play Integral Role in Growth of California Cannabis Industry
RICHMOND, Calif. – April 4, 2018 /Canna Newswire/ – Indigo Therapeutics has been named a finalist chosen to present at the CNvest: Terps and Tech cannabis industry startup and investor conference next week. The company will pitch an audience of accredited investors and media at the CNvest: Terps and Tech 2018 conference, taking place at the Hilton San Jose on April 9. Investors in the audience will also select a company for the standout pitch, who will receive a $10,000 cash prize.
“Indigo’s mission is to bring pharmaceutical standards and scale to the concentrated cannabis market,” said John Russo, Founder and CEO of Indigo Therapeutics. “Our white label approach gives us a unique opportunity to partner with new and established boutique growers and brands, delivering high quality, high purity products that are consistent and cost-effective.”
CNvest entries were received from startups seeking funding located across North America, from Southern California to Eastern Canada. The sixteen CNvest finalists earned top scores on a set of criteria critical in determining both a company’s market and investment potential. Entries were analyzed by cannabis industry editors, reporters and influencers whose background make them uniquely qualified to uncover aspects of businesses that could help them thrive in the complex cannabis market.
“As a journalist covering the cannabis industry, I’m always scouting for new, innovative businesses that are solving real problems, and entrepreneurs in this space who have a vision and are driven to succeed,” said author of the book Start Your Own Cannabis Business and mainstream media cannabis reporter, Javier Hasse, one of the eight CNvest: Terps and Tech judges. “Being a part of the CNvest judging team has been an eye-opening experience and I look forward to seeing all the finalists further develop and present their pitches. I hope CNvest will play an important role in these sixteen companies’ financing and market success.”
Indigo operates out of a state-of-the-art research and development facility that is licensed by the state for both recreational and medical markets. Led by a team of cannabis industry experts and business veterans, Indigo’s engineers have developed and refined new methods of extracting, refining and formulating concentrated cannabis across the cannabis demand spectrum. As California’s recreational cannabis market enters the next phase of regulation, Indigo is poised to increase its manufacturing, as well as beef up its sales and marketing, to increase the supply to meet the demand currently in the market.
Accredited investors wishing to attend can purchase tickets at: https://cannanewswire.co/cnvest/purchase-tickets/
About Indigo Therapeutics
Indigo Therapeutics has developed multiple methods of cannabis extraction for vape cartridges, shatter, THC-A crystalline and water-soluble formulations. With licenses for both manufacturing and distribution, plus a large R&D facility, Indigo focuses on delivering a highly consistent, scalable distillate to the market. Indigo ensures all products meet or exceed all CA quality and purity standards. Its “white label” approach —producing oils that can be branded and packaged for other companies — allows partners to focus on developing a strong brand presence. For more information visit www.indigoextracts.com.
About Canna Newswire and CNvest
CNvest™ is produced by Canna Newswire™, the cannabis industry’s platform for making news. The inaugural event, CNvest: Terps and Tech, is a cannabis science and technology startup and investment conference co-located with the Terpenes and Testing World Conference, April 9, 2018 in San Jose, California. CNvest’s mission is to become a leading platform for early stage cannabis startups seeking funding to network with cannabis investors and build their brands in the market. For more information visit www.cnvestevent.com. Follow CNvest on Twitter: @cnvestevent #cnvest
# # #
Holly Glover for Indigo Therapeutics